Kornimate/medical-research-clean huggingface dataset:
41.8 degree centigrade whole body hyperthermia for the treatment of rheumatoid diseases

Conditions: Rheumatic Diseases

Summary: recently a non-toxic system for whole body hyperthermia (wbh) used at the university of wisconsin has been shown to induce soluble tumor necrosis factor-receptor (stnf-r) i and ii when patients are heated systemically to 41.8c for 60 minutes. this observation might provide a biological basis for the therapeutic application of wbh to rheumatoid diseases, for which there is a positive anecdotal clinical experience. inherent in the hypothesis which is the basis for this protocol is the concept that the induction of tnf receptors by wbh may induce a remission in patients with active rheumatoid arthritis. beyond clinical response the biological endpoint for this investigation includes cytokine levels, tnf levels, stnf-r levels and changes in cellular tnf receptors.


Eligibility criteria:
inclusion criteria: * patients are required to meet the criteria of the american college of rheumatology (acr)for rheumatoid arthritis. * patients should be in functional class ii, or iii according to the criteria of the acr. * all candidates must be unsuccessfully treated (lack of efficacy) with at least two of the following disease-modifying antirheumatic drugs: hydroxychloroquinine, oral or injectable gold, methotrexate, azathioprine, penicillamine, and sulfasalazine. * patients receiving nonsteroidal antiinflammatory drugs (nsaids), corticosteroids (\<= 10 mg per day), or both are eligible if the dosage has been stable for at least four weeks before treatment and remained so throughout the study and follow-up period (the use of narcotics for pain flares is allowed). * the necessary degree of disease activity at enrollment should be confirmed by a finding of 10 or more swollen joints, 12 or more tender joints, and one of the following two criteria: a westergren erythrocyte sedimentation rate of at least 28 mm per hour or a serum c-reactive protein level of more than 2.0 mg per deciliter; or morning stiffness for at least 60 minutes. * patients must have adequate bone marrow function, adequate liver function, adequate renal function, calcium and electrolytes. * patients must have a dobutamine stress echo, or exercise cardiac muga, or exercise echo scan prior to entry and must fulfill certain criteria to be eligible. the spirit of the criteria are to rule out organic heart disease. * respiratory status: patients who have fev1 of \>= 60% of predicted, as well as a maximum voluntary volume (mvv) of \>= 60% of predicted, and blood gases with a po2 of \>= 60 or oxygen saturation of \>= 90% are eligible.

Keywords: rheumatoid diseases
improved robotic-assisted radical prostatectomy for locally advanced prostate cancer: bladder suspension and preliminary outcomes

Conditions: Robotic-Assisted Radical Prostatectomy; Locally Advanced Prostate Cancer; Bladder Suspension

Summary: this study is a prospective, single-center clinical trial. it aims to establish an improved robotic-assisted radical prostatectomy for treating locally advanced prostate cancer. the technique evaluates the impact of preserving the anterior peritoneum of the bladder on postoperative bladder descent and urinary control recovery. a retrospective analysis compares this modified approach with traditional anterior approach surgery, assessing differences in oncological outcomes, early functional recovery, and postoperative complication rates. the goal is to provide new theoretical foundations and technical support for the prevention and treatment of postoperative urinary incontinence.


Eligibility criteria:
inclusion criteria: 1. prostate biopsy and clinical confirmation of high-risk prostate cancer (psa \> 20 ng/ml, gleason score ≥ 8, or ct stage ≥ t2c) followed by robotic-assisted radical prostatectomy 2. multiparametric mri (mpmri) with a 3.0 t scanner for prostate or pelvic scans performed within 30 days before the operation at our center 3. eastern cooperative oncology group (ecog) performance status score between 0 and 1 4. complete clinical and prostate biopsy pathological data. 5. general health is good, with no infections, autoimmune diseases, hematologic disorders, or other malignancies. exclusion criteria: 1. presence of surgical contraindications. 2. refusal of enhanced mpmri imaging.

Keywords: robotic-assisted radical prostatectomy locally advanced prostate cancer bladder suspension
postural control in degenerative and inflammatory diseases of the hip

Conditions: Hip Osteoarthritis; Hip Arthritis

Summary: patients with primary hip osteoarthritis (oa group) and patients with inflammatory hip disease (ra group) and healthy subjects (control group) are enrolled in the study. the aim of our study is to determine the postural control in patients suffering from oa and ra of the hip joint during different conditions, i.e., on both stable and compliant surfaces with opened or closed eyes to determine the possible differences between these two diseases in this respect.

determination of functional status, using the following outcome measures: harris hip score, the functional status of the hip joint is rated with the harris hip score (hhs), visual analogue scale, western ontario and mcmaster universities osteoarthritis index, timed up \& go test. posturography measurements, postural control tests the clinical test of sensory interaction on balance (ctsib) uses different conditions to test how people adapt to changing sensory conditions during the maintenance of stance. we used the modified ctsib by neurocom to perform the test on a computerized force plate to measure the body sway. static postural stability \[displacement of centre of pressure (cop)\] was measured during standing on a single force platform (stabilometer, zwe-pii) for 20-s periods in a quiet room. signals were amplified and sampled at 16 hz via an analogue-to-digital converter. subjects stood barefoot on the platform, with the feet positioned side by side and arms hanging freely at their side. toe-out was positioned to subjects' comfort. the cop excursions along antero-posterior (ap) and medio-lateral (ml) axes were performed both on firm (the stable surface of the platform) and foam surfaces \[an airex balance pad (dimensions: 50 cm length x 41 cm width x 6 cm height) placed on the platform\], always starting with standing on the stable surface. in each condition, subjects had to stand first with the eyes open (eo), when subjects had to look at a target fixed at eye level at a distance of approximately 1 m, and then measurements were also performed with closed eyes (ec).

Eligibility criteria:
inclusion criteria: * c-reactive protein and westergreen values had to be under the upper level of the normal values. * patients should have unilateral hip pain on most of the days for several months * controls should have no hip pain or functional impairment in the hip joint or any other joint of the lower extremities. exclusion criteria: * history of trauma to the hip joint or in the pelvic region, * previous hip fracture or hip surgery, * hip joint infection and congenital or developmental diseases * any complaints in the other joints of the lower limbs * any disease that could worsen their physical or balance parameters * cancer, * endocrine, * cerebrovascular disease, * parkinson's syndrome, * epilepsy, * polyneuropathy, * neuromuscular disorder, * cardiovascular disease without medication, * atherosclerosis of the lower extremities

Keywords: hip, postural control, degenerative, inflammation
trauma informed intervention to support engagement in hiv care among msm (thrive+)

Conditions: HIV/AIDS; Trauma

Summary: this purpose of this project is to specify and provide an initial test of a 10 session, individual-based cognitive therapy intervention to address symptoms of ptsd and poor engagement in hiv care among men who have sex with men (msm) with trauma histories

the proposed intervention will incorporate the most current approaches to mediating trauma responses and stressors related to experiences of hiv stigma and homonegativity with cognitive-processing therapy, an empirically validated, cognitive-behavioral intervention for reducing negative consequences of traumatic stress. this intervention intends to improve uptake of hiv care in the prevention, engagement, and care cascade while also addressing the mental health needs of hiv-positive persons in a program of research that leads to outcomes in the short-term. if found to be efficacious, this intervention can also be scalable across clinical settings. the study will be implemented at the fenway institute at fenway health (tfi) and at ryerson university, toronto, canada and drs. o'cleirigh and hart will assume the responsibility of coordinating the study across sites. randomization will be to the 10 session intervention or to two medication adherence/engagement in care sessions.

Eligibility criteria:
inclusion criteria: * hiv-infected * is a man who has sex with men * has a history of trauma and is experiencing trauma-related distress (as operationalized by a score of \>/= 20 on the davidson trauma scale) * is sub-optimally engaged in hiv care (as operationalized by missing 1 or more hiv care appointments in the past 12 months, having a detectable viral load at most recent testing, or having poor adherence - \</=80% - to hiv medications) exclusion criteria: * has a significant mental health diagnosis that requires immediate treatment (e.g., acute major depression; panic disorder; any psychotic disorder) * unable to complete the informed consent process (e.g., substantial cognitive impairment, inadequate english language skills).

Keywords: msm hiv/aids trauma engagement in care
comparison of video-based versus written patient education on sunscreen

Conditions: Dermatology Disease; Skin Cancer

Summary: the purpose of this study is to compare the effect of video-based patient education with written instruction on subjects' adherence to sunscreen application.

we plan to conduct a randomized, controlled trial comparing the effect of video-based patient education with written instruction on subjects' adherence to sunscreen application. subjects randomized to the video-based education arm will be instructed to watch a video on the importance of sunscreen application and the proper technique of applying sunscreen. subjects randomized to the written education arm will receive written information on the importance of sunscreen application and the proper technique of applying sunscreen. the contents of the video and the written educational materials will be comparable. at the end of the study period, 3 months later, subjects will be interviewed via telephone regarding their sunscreen application behavior during the last month of the study period. subjects will also be interviewed regarding their comprehension and attitude towards video-based and written education materials.

Eligibility criteria:
inclusion criteria: * 18 years of age or older at time of consent, may be men or women. * able to adhere to the study visit schedule and other protocol requirements. * capable of giving informed consent. exclusion criteria: * non-english speaking individuals * individuals with a known allergy to sunscreens * individuals with a history of psoriasis, because phototherapy has been shown to be beneficial for their skin condition

Keywords: patient education dermatology patient education sunscreen sunscreen education skin cancer
efficacy study exploring the effects on cognition of sertindole versus comparator in patients with schizophrenia

Conditions: Schizophrenia; Cognition

Summary: the objective of this study is to explore the neurocognitive efficacy of sertindole versus comparator in patients with schizophrenia using the mccb.

sertindole is an atypical antipsychotic approved in the european union (eu) for use in patients with schizophrenia who are intolerant to at least one other antipsychotic agent. during clinical development sertindole was found to be as effective in the treatment of schizophrenia as the first-generation antipsychotic haloperidol and as the second-generation antipsychotic risperidone. sertindole is generally well tolerated and has a benign side-effect profile, including an absence of sedation, no effect on plasma prolactin levels, moderate weight gain, no anticholinergic-mediated cognitive impairment and a low rate of extrapyramidal symptoms (eps). sertindole has been shown to prolong the qt interval and is contraindicated in patients with prolonged qt interval and in patients receiving drugs known to significantly prolong the qt interval. the study is designed to provide data on the neurocognitive properties of sertindole versus quetiapine in patients with schizophrenia. efficacy for cognitive impairment is assessed in patients who are in a stable phase of their illness, with a predefined maximum level of symptoms that will allow them to be included in the study. prior antipsychotic medication will be withdrawn (down-tapered) and patients will be randomly assigned to one of the study drugs. cognitive deficiencies are an important feature of schizophrenia and correlate strongly with functional impairment. improving functional outcomes in schizophrenia has a high priority and has resulted in the initiation of a program called measurement and treatment research to improve cognition in schizophrenia (matrics) leading to the development of a neuropsychological test battery, the mccb which is used in this study.

Eligibility criteria:
inclusion criteria: * primary diagnosis of schizophrenia * man or woman, aged between 18 and 55 years exclusion criteria: * current axis i primary psychiatric diagnosis other than schizophrenia * not previously received antipsychotic drugs for schizophrenia * acute exacerbation requiring hospitalisation within the last 3 months * clinically significant extrapyramidal symptoms * clinically significant cardiovascular disease, congestive heart failure, cardiac hypertrophy, arrhythmia or bradycardia * congenital long qt syndrome or a family history of this disease, or known acquired qt interval prolongation * significant ecg abnormalities * hypokalaemia or hypomagnesaemia * in concurrent treatment with drugs inhibiting the p450 enzymes system cyp3a

Keywords: schizophrenia cognition matrics consensus cognitive battery
budesonide with intratracheal surfactants in extremely preterm infants

Conditions: Bronchopulmonary Dysplasia; Respiratory Distress Syndrome in Premature Infant

Summary: this is a phase i/ii trial in preterm infants aimed at identifying the optimal dose of budesonide with bovine lipid extract surfactant as vehicle for intratracheal administration.

premature infants of gestational age less than 29 weeks with respiratory distress syndrome and clinical indication for surfactant administration will be recruited for this phase i/ii open-label study. a total of 30 subjects will be recruited from 2 neonatal intensive care units: 1. children's hospital-health sciences centre (hsc), winnipeg 2. st. boniface general hospital, winnipeg, mb 3 groups of 10 infants each will receive single dose of intratracheal budesonide (0.0625 mg/kg, 0.125 mg/kg, and 0.25 mg/kg) with bles surfactant (5 ml/kg). pk/pd analysis will be done using clinical parameters, serum biomarkers, tracheal aspirate biomarkers and plasma budesonide levels obtained at fixed intervals. the duration of subject participation will involve 12-17 weeks for the clinical intervention, depending on gestational age at birth and discharge date. participants will be followed until 40 weeks or discharge, whichever comes first.

Eligibility criteria:
inclusion criteria: 1. male or female infant born between 23 and 28+6 weeks of ga 2. infant diagnosed with rds according to clinical protocol criteria 3. able to adhere to surfactant administration protocol 4. the patient is born in the study centre. 5. subject's parent(s)/legal guardian(s) has provided signed and dated informed consent and authorization to use protected health information, as required by national and local regulations. 6. in the investigator's opinion, the subject's parent(s)/legal guardian(s) understand(s) and can comply with protocol requirements, instructions, and protocol-stated restrictions, and is likely to complete the study as planned. exclusion criteria: 1. older than five days at inclusion. 2. presence of known clinically significant congenital heart disease or other major congenital malformation 3. subjects with clinically significant laboratory abnormalities which are deemed by the investigator to represent a safety risk to participation in this study. other laboratory parameters outside the reference range for the subject's age may be included if the investigator considers the abnormalities unlikely to introduce additional risk factors and will not interfere with data interpretation.

Keywords: surfactant budesonide steroid intratracheal preterm bronchopulmonary dysplasia respiratory distress syndrome bovine lipid extract surfactant
investigation of food effect and gastric ph increase on the bioavailability of faldapravir

Conditions: Healthy

Summary: the primary objective of this trial is to investigate the effect of food and of gastric ph increase on the relative bioavailability of faldaprevir.


Eligibility criteria:
inclusion criteria: 1. healthy male and female subjects exclusion criteria: 1. any relevant deviation from healthy condition
assessment of drug-eluting ureteral stent on bacterial adherence and biofilm formation

Conditions: Renal Calculi; Ureteral Obstruction

Summary: the purpose of this study is to determine the clinical effects of a triclosan stent on adherent bacteria, stent biofilms, and patient urine cultures in patients with an indwelling triclosan ureteral stent. the patient populations that will be tested include: patients following ureteroscopy and patients scheduled to undergo shockwave lithotripsy who require a ureteral stent. it is hypothesized that triclosan eluting ureteral stents will reduce the number of bacteria both on (within biofilm) and around (in the urine) a ureteral stent.


Eligibility criteria:
inclusion criteria: * patients who undergo ureteroscopy for any reason and require a ureteral stent post-operatively as determined by the surgeon (e.g. renal obstruction, ureteral edema, ureteral perforation, large stone fragments to pass, following ureteral dilation, ureteral trauma, solitary kidney, or any other reason left to the discretion of the surgeon). * patients undergoing extracorporeal shockwave lithotripsy (eswl) who will require a stent as determined by the treating urologist (e.g. solitary kidney, ureteral stone \> 1 cm, renal stone \> 1.5 cm, significant renal obstruction, history of pyelonephritis, or any other reason left to the discretion of the surgeon). * patients who have or are going to have chronic ureteral stents, for any reason. * patients willing to return to st. joseph's hospital's urology clinic for follow-up. exclusion criteria: * age ≤ 17 years * patients unable to consent. * any patient requiring endocarditis or prosthetic device prophylaxis (e.g. fresh arthroplasty etc.). * pregnant females * immunocompromised patients * significant urinary symptoms (urgency, dysuria, strangury, hematuria) or other bladder pathology that may cause these symptoms (e.g. interstitial cystitis) * anyone in the investigator's opinion that would be unsuitable.

Keywords: urolithiasis ureteral stent triclosan drug eluting
evaluation of major cardiovascular events in participants with, or at high risk for, cardiovascular disease who are statin intolerant treated with bempedoic acid (etc-1002) or placebo

Conditions: Cardiovascular Diseases; Statin Adverse Reaction

Summary: the purpose of this study is to determine if treatment with bempedoic acid (etc-1002) versus placebo decreases the risk of cardiovascular events in participants who have or are at high risk for cardiovascular disease and are statin intolerant.


Eligibility criteria:
inclusion criteria: * age between 18 and 85 years * history of, or at high risk for, cardiovascular disease (cvd) including coronary artery disease, symptomatic peripheral arterial disease, cerebrovascular atherosclerotic disease, or at high risk for a cardiovascular event * participant-reported si due to an adverse safety effect that started or increased during statin therapy and resolved or improved when statin therapy was discontinued resulting in an inability to tolerate: * 2 or more statins at any dose, or * 1 statin at any dose and unwilling to attempt a second statin or advised by a physician to not attempt a second statin. please note that participants currently tolerating very low dose statin therapy (an average daily dose of rosuvastatin \<5 mg, atorvastatin \<10 mg, simvastatin \<10 mg, lovastatin \<20 mg, pravastatin \<40 mg, fluvastatin \<40 mg, or pitavastatin \<2 mg) are considered to be intolerant to that low dose statin. patients may continue taking very low dose statin therapy throughout the study provided that it is stable (used for at least 4 weeks prior to screening) and well tolerated. * written confirmation by both participant and investigator that the participant is statin intolerant as defined above, aware of the benefit of statin use to reduce the risk of mace including death, and also aware that many other participants who are unable to tolerate a statin are able to tolerate a different statin or dose. * men and nonpregnant, nonlactating women * fasting blood ldl-cholesterol ≥ 100 (2.6 mmol/l) at screening exclusion criteria: * fasting blood triglycerides greater than 500 mg/dl (5.6 mmol/l) at screening * recent (within 90 days of screening) history of major cardiovascular events, transient ischemic attack (tia), or unstable or symptomatic cardiac arrhythmia * history of severe heart failure * uncontrolled hypertension or uncontrolled diabetes
the effect of hazelnut flour on blood glucose

Conditions: Obesity; Celiac Disease; Blood Glucose; Flour Sensitivity

Summary: one of the factors affecting human health is nutrition. the effects of foods on blood glucose are still under investigation. the glycemic index (gi), which is associated with many diseases today, is a value that measures the rate at which carbohydrate-containing foods raise blood glucose. it is thought that the loaves of bread produced will be a product with low gi value and can be consumed by celiacs and diabetics. it is aimed to investigate the effect of adding different amounts of hazelnut flour to bread recipes using gluten-free corn flour on blood glucose.


Eligibility criteria:
inclusion criteria: * the study group consisted of volunteer individuals aged between 18 and 35 years. * the first blood glucose measurement was taken after at least 8 hours of fasting and any of the bread types were given to the participants for consumption. * during the measurements, the volunteers were observed to avoid water, coffee, and any food intake and to avoid excessive exercise. exclusion criteria: * pregnant, * lactating women * patients with physician-diagnosed chronic diseases

Keywords: obesity celiac disease blood glucose flour sensitivity